Hyderabad-based pharmaceutical company Aurobindo Pharma's profit is likely to increase 25 percent year-on-year to Rs 465.54 crore and revenue may rise 19.5 percent to Rs 3,443.4 crore, according to analysts polled by CNBC-TV18. Earnings will be announced on November 6.
Sales growth during the quarter may be aided by improving traction in US business and higher anti-retroviral sales (ARV).
US business, which is around 58 percent of formulation sales, is likely to grow over 30 percent led by more than 20 ANDA (abbreviated new drug application) launches over last six months (including Suprax - used for treatment of bacterial infections - in Q1). US business had grown 28.1 percent year-on-year and ARV sales growth was 31 percent in June quarter.
Europe & Rest of the World sales will be closely watched. In Q1, Europe business declined 7.1 percent but Rest of the World (RoW) revenue increased 24.6 percent year-on-year.
Active pharmaceutical ingredients (API) sales may increase 7-8 percent year-on-year during the quarter, feel analysts.
Operating profit in July-September quarter is seen rising 15 percent to Rs 731.4 crore but margin may contract by 80 basis points to 21.2 percent compared to year-ago period.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
